Zurück
nix zu holen...
Greetz flat-henri
Greetz flat-henri
Anzeige
Meldung des Tages: Goldchance mit Substanz: Warum dieses Projekt Investoren aufhorchen lässt
Depotwettbewerb USA 25 KW
Beiträge:
79
Zugriffe: 10.186 / Heute: 2
Zugriffe: 10.186 / Heute: 2
|
| ||||||||||||||
Werbung
Entdecke die beliebtesten ETFs von SPDR
Du musst die Kurse angeben, zu denen Du verkauft hast. Ich mache nicht die ganze Arbeit alleine.
Und big l., zu ANGN: allerdings seit dem 03.06 keine News mehr, würd ich nicht mehr reingehen, sieht nen bisschen nach Spekublase aus.
chart.bigcharts.com/bc3/quickchart/...12&mocktick=1&rand=9884"
Nur gute News gibt es derzeit von CTE, die sollten sich alle Mitspieler ansehen.
Gruss E.
chart.bigcharts.com/bc3/quickchart/...70&mocktick=1&rand=2934"
CardioTech Gains FDA Clearance for Heparin Coating, Opens $200 Million Market for Gish Division
WEDNESDAY, JUNE 18, 2003 8:30 AM
- PR Newswire
WOBURN, Mass., Jun 18, 2003 /PRNewswire-FirstCall via COMTEX/ -- CardioTech International, Inc. (CTE) today announced that its wholly- owned subsidiary, Gish Biomedical, Inc. ("Gish"), gained FDA clearance for its unique heparin coating to be used in conjunction with Gish's line of heart- lung bypass products. The potential market for coated heart-lung bypass products could reach $200 million annually. The entire market for heart-lung products is estimated at $500 million annually.
The GBS(TM) (Gish Biocompatible Surfaces) Coating is a heparin based, covalently bound biocompatible coating that will be used to cover the surfaces of Gish disposable products. Heparin coatings are known to inhibit blood coagulation, decrease the risk of Systemic Inflammatory Response Syndrome, reduce complement activation and platelet adhesion, reduce blood loss and hemolysis, provide stable antithrombotic activity and reduce thrombus formation, as well as decrease leucocyte (white blood cells) activation.
Douglas E. Whittaker, President of Gish, stated: "The regulatory approval of the GBS line represents a milestone in the history of Gish. Until now, Gish was effectively shut-out of the lucrative coated-product business. Our high performance GBS coating will enable us to effectively compete in this market and continue to gain market share both domestically and abroad. Because we currently sell our heart-lung products to over 300 hospitals worldwide, we have a direct entree into this market sector. We plan to aggressively pursue this market worldwide."
Dr. Michael Szycher, CEO of CardioTech, stated, "Gaining regulatory clearance for the GBS coating required six separate FDA submissions, one for each of the heart-lung bypass products offered by Gish. This effort required the close coordination between engineering, regulatory and manufacturing functions. We commend the Gish technical team for their expertise and professionalism."
Gish designs, manufactures, and markets disposable medical devices for various surgical specialties including cardiovascular surgery, orthopedics, and oncology. All of Gish's products are single use disposable products or have a disposable component. Gish's principal products include custom cardiovascular tubing systems, blood reservoirs, cardioplegia delivery systems, oxygenators, central venous access catheters and ports, and blood recovery devices for post-operative use in orthopedic surgeries. Gish markets its products worldwide through a combination of direct sales representatives and specialty medical distributors.
About CardioTech:
CardioTech International, Inc. maintains operations in Woburn, Massachusetts, Plymouth, Minnesota and Rancho Santa Margarita, California. CardioTech focuses on developing and marketing devices to treat cardiovascular disease.
Current revenue sources for CardioTech include patented medical grade polyurethanes for use in implantable medical devices, disposable devices manufactured on an OEM basis for Fortune 100 companies, cardiovascular tubing systems, arterial filters, oxygenators, cardioplegia delivery systems and oxygen saturation monitors. The Company also expects to begin the manufacturing and marketing of two FDA cleared wound dressing technologies in the near future. The wound dressings address a $300 million annual market. CardioTech is currently in clinical trials with a synthetic coronary artery bypass graft that addresses a potential market of $1.5 billion annually.
CardioTech believes that this release contains forward-looking statements that are subject to risks and uncertainties. Such statements are based on management's beliefs and are subject to facts that could cause results to differ materially from the forward-looking statements. For further information you are encouraged to review CardioTech's filings with the Securities and Exchange Commission.
Und big l., zu ANGN: allerdings seit dem 03.06 keine News mehr, würd ich nicht mehr reingehen, sieht nen bisschen nach Spekublase aus.
Nur gute News gibt es derzeit von CTE, die sollten sich alle Mitspieler ansehen.
Gruss E.
CardioTech Gains FDA Clearance for Heparin Coating, Opens $200 Million Market for Gish Division
WEDNESDAY, JUNE 18, 2003 8:30 AM
- PR Newswire
WOBURN, Mass., Jun 18, 2003 /PRNewswire-FirstCall via COMTEX/ -- CardioTech International, Inc. (CTE) today announced that its wholly- owned subsidiary, Gish Biomedical, Inc. ("Gish"), gained FDA clearance for its unique heparin coating to be used in conjunction with Gish's line of heart- lung bypass products. The potential market for coated heart-lung bypass products could reach $200 million annually. The entire market for heart-lung products is estimated at $500 million annually.
The GBS(TM) (Gish Biocompatible Surfaces) Coating is a heparin based, covalently bound biocompatible coating that will be used to cover the surfaces of Gish disposable products. Heparin coatings are known to inhibit blood coagulation, decrease the risk of Systemic Inflammatory Response Syndrome, reduce complement activation and platelet adhesion, reduce blood loss and hemolysis, provide stable antithrombotic activity and reduce thrombus formation, as well as decrease leucocyte (white blood cells) activation.
Douglas E. Whittaker, President of Gish, stated: "The regulatory approval of the GBS line represents a milestone in the history of Gish. Until now, Gish was effectively shut-out of the lucrative coated-product business. Our high performance GBS coating will enable us to effectively compete in this market and continue to gain market share both domestically and abroad. Because we currently sell our heart-lung products to over 300 hospitals worldwide, we have a direct entree into this market sector. We plan to aggressively pursue this market worldwide."
Dr. Michael Szycher, CEO of CardioTech, stated, "Gaining regulatory clearance for the GBS coating required six separate FDA submissions, one for each of the heart-lung bypass products offered by Gish. This effort required the close coordination between engineering, regulatory and manufacturing functions. We commend the Gish technical team for their expertise and professionalism."
Gish designs, manufactures, and markets disposable medical devices for various surgical specialties including cardiovascular surgery, orthopedics, and oncology. All of Gish's products are single use disposable products or have a disposable component. Gish's principal products include custom cardiovascular tubing systems, blood reservoirs, cardioplegia delivery systems, oxygenators, central venous access catheters and ports, and blood recovery devices for post-operative use in orthopedic surgeries. Gish markets its products worldwide through a combination of direct sales representatives and specialty medical distributors.
About CardioTech:
CardioTech International, Inc. maintains operations in Woburn, Massachusetts, Plymouth, Minnesota and Rancho Santa Margarita, California. CardioTech focuses on developing and marketing devices to treat cardiovascular disease.
Current revenue sources for CardioTech include patented medical grade polyurethanes for use in implantable medical devices, disposable devices manufactured on an OEM basis for Fortune 100 companies, cardiovascular tubing systems, arterial filters, oxygenators, cardioplegia delivery systems and oxygen saturation monitors. The Company also expects to begin the manufacturing and marketing of two FDA cleared wound dressing technologies in the near future. The wound dressings address a $300 million annual market. CardioTech is currently in clinical trials with a synthetic coronary artery bypass graft that addresses a potential market of $1.5 billion annually.
CardioTech believes that this release contains forward-looking statements that are subject to risks and uncertainties. Such statements are based on management's beliefs and are subject to facts that could cause results to differ materially from the forward-looking statements. For further information you are encouraged to review CardioTech's filings with the Securities and Exchange Commission.
aber eine Frage am Rande: Wann stehst Du so auf?
Schönen Tag B.L.
Schönen Tag B.L.
Wenn ich um 4.30 Uhr morgens poste, bedeutet das, dass ich von der Nachtschicht nach Hause gekommen bin und dann schreib ich was mir so spontan einfällt.
Aufstehen gegen 14.30 Uhr, das ist ein Hauptgrund warum ich mich lieber mit Ami-Shares befasse, da bin ich stressfrei zur Eröffnung am Ball.
An zick-zock, ich hab Deine Verkaufskurse gesehen, allerdings hatte ich diese in diesem aktuellen Thread gesucht, gibt ja fast jede Woche nen Neuen.
Wünsche Pavian nen schönen Urlaub.
Gruss E.
Aufstehen gegen 14.30 Uhr, das ist ein Hauptgrund warum ich mich lieber mit Ami-Shares befasse, da bin ich stressfrei zur Eröffnung am Ball.
An zick-zock, ich hab Deine Verkaufskurse gesehen, allerdings hatte ich diese in diesem aktuellen Thread gesucht, gibt ja fast jede Woche nen Neuen.
Wünsche Pavian nen schönen Urlaub.
Gruss E.
AMRN für 3 Dollar, mal nen Schnäppchen gezogen.
Mit den News heute noch kaufen.
Gruss E.
Amarin Corporation and Acadia Pharmaceuticals Sign Pharmaceutical Development Agreement
LONDON, Jun 18, 2003 /PRNewswire-FirstCall via COMTEX/ -- Amarin Corporation
plc (Nasdaq: AMRN) today confirmed that its Swedish subsidiary, Amarin
Development AB, has been engaged to provide pharmaceutical formulation and
manufacturing services for ACADIA Pharmaceuticals, based in San Diego,
California and Copenhagen, Denmark. The deal centers on the continued
development of ACADIA's small molecule drug candidate ACP-103, currently in
Phase I clinical studies. ACADIA intends to utilize Amarin's services in
connection with additional clinical studies planned for ACP-103 for the
treatment of neuropsychiatric and neurological disorders.
Rick Stewart, CEO of Amarin, commented on the successful deal, "The selection of
Amarin Development by ACADIA to provide these services underscores our
strengthened position as a global product development company. This agreement
additionally makes use of Amarin's expertise in neurology and complements the
research and development activities of Amarin Pharmaceuticals Inc. in the US,
making this a particularly attractive signing."
About ACP-103
ACP-103 is initially being pursued as a therapy for treatment-induced
dysfunctions in Parkinson's disease, an indication that lacks adequate drug
therapy. Due to its unique profile, ACP-103 may also have broad utility in a
range of other important indications. ACP-103 is a proprietary small molecule
that acts as a selective inverse agonist at the 5-HT2A receptor.
About Amarin
Amarin Corporation plc is a specialty pharmaceutical company focused on
neurology and pain management. Amarin has multiple pharmaceutical products on
the US market along with a development pipeline that includes two late-stage
candidates: Zelapar (selegiline HCl orally disintegrating tablets) for
Parkinson's disease and LAX-101, a proprietary compound for Huntington's
Disease. For press releases and other Company information, visit our websites at
www.amarincorp.com and www.amarinpharma.com.
About ACADIA
ACADIA Pharmaceuticals is a drug discovery and development company that
efficiently discovers novel small molecule drug candidates using its proprietary
chemical-genomics platform. ACADIA has applied its platform to generate a broad
discovery pipeline directed at large unmet medical needs including Parkinson's
disease, chronic pain, psychosis, and glaucoma. Two of ACADIA's drug candidates
have been successfully advanced from initial discovery to clinical development,
and several additional programs are in late-stage preclinical testing. ACADIA's
corporate headquarters as well as its biological research facilities are located
in San Diego, California and its chemistry research facilities are located in
Copenhagen, Denmark.
Statements in this press release that are not historical facts are
forward-looking statements that involve risks and uncertainties which may cause
the Company's actual results in future periods to be materially different from
any performance suggested herein. Such risks and uncertainties include, without
limitation, risks associated with the inherent uncertainty of pharmaceutical
research, product development and commercialization, the impact of competitive
products and patents, as well as other risks and uncertainties detailed from
time to time in periodic report, including but not limited to the filing or
approval of the NDA for Zelapar. For more information, please refer to Amarin
Corporation's Annual Report for 2002 on Form 20-F and its Form 6-Ks as filed
with the U.S. Securities and Exchange Commission. The Company assumes no
obligation to update information on its expectations.
SOURCE Amarin Corporation plc
Mit den News heute noch kaufen.
Gruss E.
Amarin Corporation and Acadia Pharmaceuticals Sign Pharmaceutical Development Agreement
LONDON, Jun 18, 2003 /PRNewswire-FirstCall via COMTEX/ -- Amarin Corporation
plc (Nasdaq: AMRN) today confirmed that its Swedish subsidiary, Amarin
Development AB, has been engaged to provide pharmaceutical formulation and
manufacturing services for ACADIA Pharmaceuticals, based in San Diego,
California and Copenhagen, Denmark. The deal centers on the continued
development of ACADIA's small molecule drug candidate ACP-103, currently in
Phase I clinical studies. ACADIA intends to utilize Amarin's services in
connection with additional clinical studies planned for ACP-103 for the
treatment of neuropsychiatric and neurological disorders.
Rick Stewart, CEO of Amarin, commented on the successful deal, "The selection of
Amarin Development by ACADIA to provide these services underscores our
strengthened position as a global product development company. This agreement
additionally makes use of Amarin's expertise in neurology and complements the
research and development activities of Amarin Pharmaceuticals Inc. in the US,
making this a particularly attractive signing."
About ACP-103
ACP-103 is initially being pursued as a therapy for treatment-induced
dysfunctions in Parkinson's disease, an indication that lacks adequate drug
therapy. Due to its unique profile, ACP-103 may also have broad utility in a
range of other important indications. ACP-103 is a proprietary small molecule
that acts as a selective inverse agonist at the 5-HT2A receptor.
About Amarin
Amarin Corporation plc is a specialty pharmaceutical company focused on
neurology and pain management. Amarin has multiple pharmaceutical products on
the US market along with a development pipeline that includes two late-stage
candidates: Zelapar (selegiline HCl orally disintegrating tablets) for
Parkinson's disease and LAX-101, a proprietary compound for Huntington's
Disease. For press releases and other Company information, visit our websites at
www.amarincorp.com and www.amarinpharma.com.
About ACADIA
ACADIA Pharmaceuticals is a drug discovery and development company that
efficiently discovers novel small molecule drug candidates using its proprietary
chemical-genomics platform. ACADIA has applied its platform to generate a broad
discovery pipeline directed at large unmet medical needs including Parkinson's
disease, chronic pain, psychosis, and glaucoma. Two of ACADIA's drug candidates
have been successfully advanced from initial discovery to clinical development,
and several additional programs are in late-stage preclinical testing. ACADIA's
corporate headquarters as well as its biological research facilities are located
in San Diego, California and its chemistry research facilities are located in
Copenhagen, Denmark.
Statements in this press release that are not historical facts are
forward-looking statements that involve risks and uncertainties which may cause
the Company's actual results in future periods to be materially different from
any performance suggested herein. Such risks and uncertainties include, without
limitation, risks associated with the inherent uncertainty of pharmaceutical
research, product development and commercialization, the impact of competitive
products and patents, as well as other risks and uncertainties detailed from
time to time in periodic report, including but not limited to the filing or
approval of the NDA for Zelapar. For more information, please refer to Amarin
Corporation's Annual Report for 2002 on Form 20-F and its Form 6-Ks as filed
with the U.S. Securities and Exchange Commission. The Company assumes no
obligation to update information on its expectations.
SOURCE Amarin Corporation plc
AMARIN CORP PLC ADS - Nasdaq National Market: AMRN
Consolidated Real-time Market Quote*
Exchange Quote
Consolidated Real-time Market Quote*
| Last | Change (%) | After Hours Chg (%)** | Bid | Ask | Trade Time |
| 3.22 | N/A | 3.18 (5) | 3.25 (2) | 12:44 |
Exchange Quote
| Last | Change (%) | Bid (size) | Ask (size) | Trade Time |
| 3.27 | 3.23 (3) | 3.25 (2) | 13:06 | |
| Day Volume | Last Size | Open | High | Low |
| 178,900 | 500 | 3.10 | 3.33 | 3.07 |
| Latest Ticks | # of Trades | Avg Trade Size | VWAP | 52 Wk High |
| ===+ | 237 | 755 | 3.1987 | 8.55 |
| 52 Wk Low | Prev Close | Avg Day Vol | ||
| 2.15 | 3.01 | 149,300 |
1:40:31 PM EDT - Thursday, June 19, 2003- Exchange quote is delayed at least 15 minutes
chart.bigcharts.com/bc3/quickchart/...ocktick=1&rand=1417" style="max-width:560px" border=0>
4 Dollar sollten drin sein, meine Meinung !
Zur Zeit scheint mir aber etwas die Luft raus zu sein,insbesondere bei Biotech.Meine DNDN sinken wie Blei,obwohl für mich sehr guter Newsflow.Ich warte ab.
das war`s mit meinen 40.000,--.Gott sei Dank habe ich gestern etwas Profit mitgenommen bei RAEE.Die fallen nach der meldung gestern auch.
Schulden weiter abgebaut, Matrix scheint gut anzulaufen...
IMAX Corporation Announces Retirement of $22 Million of Debt
THURSDAY, JUNE 19, 2003 7:00 AM
- PR Newswire
TORONTO, Jun 19, 2003 /PRNewswire-FirstCall via COMTEX/ -- IMAX Corporation(Nasdaq: IMAX; TSX: IMX) today announced that it has retired approximately $22 million in face value of its $200 million of senior notes due December 2005 in exchange for newly-issued common shares of the Company. After giving effect to these transactions, approximately $178 million of the notes remain outstanding. When combined with the Company's prior debt retirements in 2001 and 2002, IMAX has reduced its total debt by more than 40% in less than two years.
"The retirement of approximately ten percent of outstanding debt is important for IMAX and we believe that this reduction facilitates our ability to refinance the remainder of the debt before December 2005 on favorable terms," said Richard L. Gelfond and Bradley J. Wechsler, IMAX's Co-Chairmen and Co-Chief Executive Officers. "Although the senior note issue is not due for another two and a half years, we are committed to improving the Company's balance sheet and will continue to seek opportunities to do so."
"Over just the last six weeks, the Company has eliminated a significant share overhang resulting from the holdings of former shareholder Wasserstein Partners, LP, successfully released The Matrix Reloaded: The IMAX Experience and now eliminated a significant portion of our remaining debt," added Messrs. Gelfond and Wechsler.
The $22 million in face value of senior notes were exchanged for approximately 2.9 million shares of IMAX common stock.
der Woche!
Bei FSST und HMSL mit fetten Tausenderpositionen reichlich Prozente gesammelt, wenn ich mich nicht irre.
Glückwunsch sach ich da ma !
Ich bin leider komplett flat.
12 gruene Werte und 12x gruener Mist, datt muss man erstma schaffen!
Nächste Woche hab ich nur gelengentlich Zeit für die Börse.
Deshalb wird es wohl auch hier, genau wie bei Happy, eine Woche lang ein 100prozentiges Cash- Depot geben.
Viel Trading- Glück für die KW 26 wünscht euch
Bei FSST und HMSL mit fetten Tausenderpositionen reichlich Prozente gesammelt, wenn ich mich nicht irre.
Glückwunsch sach ich da ma !
Ich bin leider komplett flat.
12 gruene Werte und 12x gruener Mist, datt muss man erstma schaffen!
Nächste Woche hab ich nur gelengentlich Zeit für die Börse.
Deshalb wird es wohl auch hier, genau wie bei Happy, eine Woche lang ein 100prozentiges Cash- Depot geben.
Viel Trading- Glück für die KW 26 wünscht euch
Ich muss das erst verarbeiten,aber ich denke,dass ich nur DNDN entfernen werde.Es sei denn,sie stehen genau auf SL.Dann halte ich noch eine Woche. Und EONC bleibt bis zum bitteren Ende im Depot.Habe einige Male Werte zu früh verkauft,diesmal nicht(hier verkaufe ich wenn,zu spät).
gute N8 B.L.
gute N8 B.L.
Die Woche fing gut an, dann wurds plötzlich zappenduster für die meisten Bios.
Am Montag war INGN nachbörslich noch bei 8, jetzt geschlossen zu 5. Künstlerpech.
Na, EZEN hat mir nen minimales Plus gerettet, immerhin.
reinyboy rückt mir auf den Pelz, nächste Woche werde ich wieder besser.
Ich werd auf keinen Fall mehr nen Share kaufen, über den ich aber so gar nichts weiss,
so wie EMTI diese Woche, ausser das EMTI von 0,005! auf 0,20 gestiegen war.
So was Dummes muss bestraft werden, irgend eine Bude zu kaufen, die man gar nicht kennt.
Gruss E.
mgroen.bei.t-online.de/Abrechnung%2025%20kw.jpg"
Am Montag war INGN nachbörslich noch bei 8, jetzt geschlossen zu 5. Künstlerpech.
Na, EZEN hat mir nen minimales Plus gerettet, immerhin.
reinyboy rückt mir auf den Pelz, nächste Woche werde ich wieder besser.
Ich werd auf keinen Fall mehr nen Share kaufen, über den ich aber so gar nichts weiss,
so wie EMTI diese Woche, ausser das EMTI von 0,005! auf 0,20 gestiegen war.
So was Dummes muss bestraft werden, irgend eine Bude zu kaufen, die man gar nicht kennt.
Gruss E.
Reiny und ZiZo, mit Pavian und Grueni kann ich mir ja die Hand reichen, zu viele Bios das war das Schlagwort und kein gesundes Mix.
Greetz flat-henri
Greetz flat-henri
ich poste moregn,wenn Du einverstanden bist.Wir haben gliech das Haus voll,die alte Skatrunde trifft sich.
Schön,dass nach 8 Wochen Sommer in Berlin endlich heute der Herbst Einzug gehalten hat, 16 C, Wind und Regen,die besten Voraussetzungen für die geplante Gartenparty.
Ach so: Kann ich die SL von letzter Woche behalten,z.B bei DNDN?
Ciao B.L.
Schön,dass nach 8 Wochen Sommer in Berlin endlich heute der Herbst Einzug gehalten hat, 16 C, Wind und Regen,die besten Voraussetzungen für die geplante Gartenparty.
Ach so: Kann ich die SL von letzter Woche behalten,z.B bei DNDN?
Ciao B.L.
Erst mal herzlichen Dank für deine Mühen.
FSST wurde ja glücklicherweise am letzten Dienstag zu 0.22 $ versilbert. Inzwischen liegen die ja auch da wo sie hingehören bei unter 10 Cent.
Verkauft wird nun alles was noch im Depot ist:
SONT = 18018$
IMA = 11070$
HMSL = 23680$
Gekauft wird :
KRY 6250 Stück zu SK 1.60$ = 10000$
CAU 7000 Stück zu SK 1.40$ = 9800$
WHT 8000 Stück zu SK 1.22$ = 9760$
MNG 7500 Stück zu SK 1.26$ = 9450$
GSS 3700 Stück zu SK 2.71$ = 10027$
VGZ 2900 Stück zu SK 3.40$ = 9860$
IAG 1800 Stück zu SK 5.21$ = 9899$
KGC 1500 Stück zu SK 6.97$ = 10455$
BVN 320 Stück zu SK 30.99$ = 9916.80$
Ich weiß, das Depot ist nun sehr einseitig, aber ich glaube an ne outperformence für die nächste Woche ( Wochen??).
Grüße Reiny
FSST wurde ja glücklicherweise am letzten Dienstag zu 0.22 $ versilbert. Inzwischen liegen die ja auch da wo sie hingehören bei unter 10 Cent.
Verkauft wird nun alles was noch im Depot ist:
SONT = 18018$
IMA = 11070$
HMSL = 23680$
Gekauft wird :
KRY 6250 Stück zu SK 1.60$ = 10000$
CAU 7000 Stück zu SK 1.40$ = 9800$
WHT 8000 Stück zu SK 1.22$ = 9760$
MNG 7500 Stück zu SK 1.26$ = 9450$
GSS 3700 Stück zu SK 2.71$ = 10027$
VGZ 2900 Stück zu SK 3.40$ = 9860$
IAG 1800 Stück zu SK 5.21$ = 9899$
KGC 1500 Stück zu SK 6.97$ = 10455$
BVN 320 Stück zu SK 30.99$ = 9916.80$
Ich weiß, das Depot ist nun sehr einseitig, aber ich glaube an ne outperformence für die nächste Woche ( Wochen??).
Grüße Reiny
N`Abend!
Danke erstmal für deine Wochenabrechnung!
Katastrophale 5 Tage für meine 12 Heifleier is datt geworden.
Und du sprachst noch vor Tagen vom gruenen Wochengewinner *gg*!
Ich Keule hab am Ende aber doch noch so richtig Pech jehabt, Künstlerpech eben!
Ein bisschen Zeit is aber um neue Absacker fürs gruene Depot zu suchen.
Obwohl ich nächste Woche (hauptsächlich Nachmittags) echt kaum Zeit für den Markt habe,
trete ich an.
82368 Dollar stehen zur Verfügung.
8 Werte werden aufgenommen.
82368 : 8 = 10296!
Macht also 10296 je Position.
01 GILTF KK 5,19 (Stk. 1984 ) = 10296
02 SLGLF KK 0,21 (Stk. 49028) = 10296
03 BOAI KK 0,13 (Stk. 79200) = 10296
04 FAIM KK 1,72 (Stk. 5986 ) = 10296
05 CHINA KK 7,29 (Stk. 1412 ) = 10296
06 IPIX KK 4,74 (Stk. 2172 ) = 10296
07 EONC KK 1,40 (Stk. 7354 ) = 10296
08 AEGN KK 0,68 (Stk. 15141) = 10296
So, ma gucken, watt meine schnell aus der Hüfte geschossenen Werte in den nächsten Tagen veranstalten.
2 Tage FED Sitzung und viele US- Wirtschaftsdaten sollten für reichlich Bewegung am Aktienmarkt sorgen.
Fragt sich nur in welche Richtung!?
Eigentlich erscheint es aus diesem Grund eher sinnvoll etwas an der Aktien- Seitenlinie zu warten, aber ganz ohne "Spielspass" macht es wenig Laune!
Deshalb, keine Runde ohne
Danke erstmal für deine Wochenabrechnung!
Katastrophale 5 Tage für meine 12 Heifleier is datt geworden.
Und du sprachst noch vor Tagen vom gruenen Wochengewinner *gg*!
Ich Keule hab am Ende aber doch noch so richtig Pech jehabt, Künstlerpech eben!
Ein bisschen Zeit is aber um neue Absacker fürs gruene Depot zu suchen.
Obwohl ich nächste Woche (hauptsächlich Nachmittags) echt kaum Zeit für den Markt habe,
trete ich an.
82368 Dollar stehen zur Verfügung.
8 Werte werden aufgenommen.
82368 : 8 = 10296!
Macht also 10296 je Position.
01 GILTF KK 5,19 (Stk. 1984 ) = 10296
02 SLGLF KK 0,21 (Stk. 49028) = 10296
03 BOAI KK 0,13 (Stk. 79200) = 10296
04 FAIM KK 1,72 (Stk. 5986 ) = 10296
05 CHINA KK 7,29 (Stk. 1412 ) = 10296
06 IPIX KK 4,74 (Stk. 2172 ) = 10296
07 EONC KK 1,40 (Stk. 7354 ) = 10296
08 AEGN KK 0,68 (Stk. 15141) = 10296
So, ma gucken, watt meine schnell aus der Hüfte geschossenen Werte in den nächsten Tagen veranstalten.
2 Tage FED Sitzung und viele US- Wirtschaftsdaten sollten für reichlich Bewegung am Aktienmarkt sorgen.
Fragt sich nur in welche Richtung!?
Eigentlich erscheint es aus diesem Grund eher sinnvoll etwas an der Aktien- Seitenlinie zu warten, aber ganz ohne "Spielspass" macht es wenig Laune!
Deshalb, keine Runde ohne
brauch nur Deine Kürzel sehen, dann klingelts bei mir. IPIX, CHINA, kommen mir alle sehr bekannt vor. Na, ich hab noch gar nicht gescannt und richtig hingesehen, es fällt mir aber bestimmt noch was Nettes ein.
AMRN, EZEN, OME und JNIC bleiben aber wohl drin.
Melde mich wieder,
Gruss E.
AMRN, EZEN, OME und JNIC bleiben aber wohl drin.
Melde mich wieder,
Gruss E.
Ich behalte nur AMRN, EZEN, OME.
Neuaufnahmen sind alte Bekannte,
CELL, WSTL, PMTI, SGDE, FSTW, CHRB, CFI, NAUT, ATCO.
Gruss E.
Neuaufnahmen sind alte Bekannte,
CELL, WSTL, PMTI, SGDE, FSTW, CHRB, CFI, NAUT, ATCO.
Gruss E.
Die Lage ist mir nach wie vor zu unsicher, um komplett in den Markt zu gehen; alleine die anstehende Zinsentscheidung kann für ordentlich Turbulenzen sorgen. Mit einem Bein bleibe ich trotzdem drin.
ICGE ist ja ausgestopt worden(eigentlich erstaunlich, dass es nach dem Run nur noch bergab ging) - demnach Cash=31612$
Neu ins Depot wandert TRAD(300*10=3000$/Cash=28612$), nachdem die Umsätze weiterhin hoch sind an den Börsen, sollte sich das auch bei den Zahlen von TRAD auswirken. SL setze ich bei 8,9!
Ansonsten bleibt alles wie bisher.
Glückwunsch an Reiny für das gute Timing mit der Pleiteaktie und an B.L mit RAEE!
Danke für die Arbeit, Eskimato und auf eine erfolgreichere Woche!
ICGE ist ja ausgestopt worden(eigentlich erstaunlich, dass es nach dem Run nur noch bergab ging) - demnach Cash=31612$
Neu ins Depot wandert TRAD(300*10=3000$/Cash=28612$), nachdem die Umsätze weiterhin hoch sind an den Börsen, sollte sich das auch bei den Zahlen von TRAD auswirken. SL setze ich bei 8,9!
Ansonsten bleibt alles wie bisher.
Glückwunsch an Reiny für das gute Timing mit der Pleiteaktie und an B.L mit RAEE!
Danke für die Arbeit, Eskimato und auf eine erfolgreichere Woche!
Es gibt keine neuen Beiträge.
|
Neueste Beiträge aus dem Huaneng Power ADR Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
| Huaneng | skunk.works | 22.04.08 15:09 | ||||
| 78 | Depotwettbewerb USA 25 KW | Eskimato | Eskimato | 17.07.03 07:28 |